Adial Pharmaceuticals changes name to Azora Therapeutics
ADIL•Adial Pharmaceuticals changed its name to Azora Therapeutics and expects its common stock to begin trading on Nasdaq under ticker AZR on October 29, 2026.
1. Name and leadership change
Adial Pharmaceuticals changed its name to Azora Therapeutics and appointed Matt Davidson president and chief executive officer to lead the new executive team.
2. Drug development and cash
The company expects its lead candidate, AT177, an oral, colon-targeted AhR agonist for ulcerative colitis, to enter Phase 1 trials in the first half of 2027. It expects current cash and cash equivalents to fund operational plans into 2028.
